Biblio

Author Title [ Type

] Year

Filters: Author is Fröhling, Stefan [Clear All Filters]

Journal Article

Rheinnecker M, Fröhlich M, Rübsam M, Paramasivam N, Heilig CE, Fröhling S, Schlenk RF, Hutter B, Hübschmann D. ZygosityPredictor. Bioinform Adv. 2024;4(1):vbae017.

Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, et al. Trailblazing Precision Medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2021.

Wurm AA, Brilloff S, Kolovich S, Schäfer S, Rahimian E, Kufrin V, Bill M, Carrero ZI, Drukewitz S, Krüger A, et al. Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity. Cell Rep Med. 2023:101200.

Kreutzfeldt S, Horak P, Hübschmann D, Knurr A, Fröhling S. National Center for Tumor Diseases Precision Oncology Thesaurus for Drugs: A Curated Database for Drugs, Drug Classes, and Drug Targets in Precision Cancer Medicine. JCO Clin Cancer Inform. 2023;7:e2200147.

Voronina N, Wong JKL, Hübschmann D, Hlevnjak M, Uhrig S, Heilig CE, Horak P, Kreutzfeldt S, Mock A, Stenzinger A, et al. The landscape of chromothripsis across adult cancer types. Nat Commun. 2020;11(1):2320.

Heilig CE, Laßmann A, Mughal SS, Mock A, Pirmann S, Teleanu V, Renner M, Andresen C, Köhler BC, Aybey B, et al. Gene expression-based prediction of pazopanib efficacy in sarcoma. Eur J Cancer. 2022;172:107-118.

Hamacher R, Pabst KM, Cheung PF, Heilig CE, Hüllein J, Liffers S-T, Borchert S, Costa PFragoso, Schaarschmidt BM, Kessler L, et al. Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor. J Nucl Med. 2024.

Scherr A-L, Nader L, Xu K, Elssner C, Ridder DA, Nichetti F, Mastel M, Fritzsche S, Kelmendi E, Schmitt N, et al. Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma. Hepatology. 2023.

Westphalen BC, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, et al. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer. 2020;135:1-7.

Thatikonda V, Islam SMAshiqul, Autry RJ, Jones BC, Gröbner SN, Warsow G, Hutter B, Huebschmann D, Fröhling S, Kool M, et al. Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. Nat Cancer. 2023.

Lauinger M, Christen D, Klar RFU, Roubaty C, Heilig CE, Stumpe M, Knox JJ, Radulovich N, Tamblyn L, Xie IY, et al. BRAF in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability. Sci Adv. 2023;9(35):eade7486.

Hübschmann D, Jopp-Saile L, Andresen C, Krämer S, Gu Z, Heilig CE, Kreutzfeldt S, Teleanu V, Fröhling S, Eils R, et al. Analysis of Mutational Signatures with YAPSA (Yet Another Package for Signature Analysis). Genes Chromosomes Cancer. 2020.